EchoSolv AS

by Echo IQ  · Based in Australia → — Identify high-probability severe aortic stenosis (sAS) patients accurately, quickly, simply.
Cardiology Cardiothoracic Surgery
Website
Claim this tool
Is this the maker? Claim the company →

Regulatory Status Disclosed

Overview

EchoSolv AS is an AI-powered clinical decision support software developed by Echo IQ. It is designed to analyze echocardiographic data to aid cardiologists in the accurate and efficient diagnosis of severe Aortic Stenosis (AS). The platform leverages a vast global dataset of echocardiograms linked to mortality, enabling it to provide consistent, unbiased, and rapid risk assessments. EchoSolv AS fits seamlessly into existing clinical workflows, offering integration with PACS systems without requiring Electronic Medical Record (EMR) integration. It provides a categorical assessment (high, medium, or low probability) of severe AS by applying proprietary AI algorithms and recognized clinical practice guidelines. The software acts as a decision support aid, enhancing the physician’s ability to review studies faster and prioritize cases that require closer attention.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered clinical decision support for severe aortic stenosis probability
  • Consistent severe AS probability and guideline check from measurements
  • Second reader support to help prioritize studies for closer review
  • Real-world readiness; AI does not use LVOT measurements
  • Faster clinical review using standardized, measurement-based AI and guideline analysis
  • Measurement-based AI (analyzes numerical measurements, not images)
  • Designed to fit existing workflows (no EMR integration required, integrates with PACS)
  • Ultra-fast risk detection (under 3 seconds)
  • Multi-site population health reporting
  • Comprehensive audit trails with role-based access controls

Use Cases

  • Aiding in the diagnosis of severe Aortic Stenosis
  • Identifying patients at risk of mortality who might benefit from further clinical review
  • Prioritizing echocardiogram studies for closer review
  • Enhancing clinical review speed and consistency for cardiologists
  • Supporting healthcare professionals in making informed decisions for improved patient outcomes
  • Reducing unconscious bias in cardiac diagnosis

What Physicians Need to Know

Echocardiography AI Features
EchoSolv is an AI-powered clinical decision support platform that analyzes echocardiogram reports and measurements to identify patients at risk for structural heart diseases, specifically severe Aortic Stenosis (AS) and Heart Failure (HF). It processes over 140 parameters from echocardiogram reports, providing probabilistic risk prediction and handling missing data. The platform offers ultra-fast risk detection (under 3 seconds) and automated assessment using AI-guided disease probability. It identifies high-risk patients who may not meet conventional clinical guidelines but demonstrate high mortality risks. EchoSolv has demonstrated superior accuracy in identifying severe AS, particularly in women and low-gradient presentations, and can help restore gender equity in diagnosis. It is built on the world's largest echocardiographic dataset linked to mortality (National Echo Database of Australia - NEDA) and analyzes data directly from reports without requiring raw image access or specialized hardware.
Heart Failure Risk Prediction
EchoSolv-HF has achieved 97% accuracy in identifying high-risk individuals who subsequently developed heart failure. In studies, the AI technology alone correctly identified 86% of heart failure patients, compared to 46% in standard clinical practice, and increased diagnosis accuracy to 97% in high-risk individuals when combined with clinical evaluation. It can predict future heart failure in individuals deemed high-risk by the AI at baseline, with those individuals subsequently hospitalized at almost ten times the rate of low-risk patients. EchoSolv HF has been clinically validated with 99.5% sensitivity and 91.0% specificity in detecting heart failure on an independent dataset from the Mayo Clinic Platform. It can also identify worsening Left Ventricular (LV) dysfunction even when key parameters are missing.
Cardiac Monitoring Integration
EchoSolv is designed to integrate seamlessly into existing clinical workflows. It is a cloud-based solution that integrates with PACS systems and can provide data via REST API. The platform analyzes data directly from echocardiogram reports and does not require EMR integration. It supports data export in PDF and CSV formats.
AHA/ACC Guideline Alignment
EchoSolv-AS incorporates the application of recognized Aortic Stenosis clinical practice guidelines, specifically the 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease. It also performs clinical guideline checks for Severe Aortic Stenosis, Diastolic Dysfunction, and Heart Failure. The technology is noted for its ability to identify high-risk echoes that may not meet all conventional guideline criteria but are concerning when all data are considered. It uses clinical guidelines to identify 100% of patients at high risk of having in-guideline aortic stenosis.
Real-Time Alert Capability
EchoSolv provides real-time insights and risk stratification, offering ultra-fast risk detection in under 3 seconds. It delivers real-time interpretations within seconds of completing the echocardiogram. The platform offers customizable alerts and can send SMS and email alerts for risk detections. Detections are available when clinicians begin writing their reports.
Physician Tip

Physicians can leverage EchoSolv to enhance the accuracy and consistency of severe Aortic Stenosis (AS) and Heart Failure (HF) diagnoses, particularly in complex cases like low-gradient AS or in women, where traditional methods might lead to underdiagnosis. The tool assists in prioritizing patient follow-up and intervention by rapidly identifying high-risk individuals, even those not fully meeting conventional guideline criteria. This can lead to improved patient outcomes through earlier detection and timely intervention, reducing missed diagnoses. EchoSolv streamlines workflow by providing real-time, AI-driven insights directly from echocardiogram reports, eliminating the need for raw image access or complex EMR integration. It also serves as a valuable second reader support to ensure no high-risk cases are overlooked.

EchoSolv is a cloud-based solution designed for seamless integration into existing clinical workflows, including PACS systems, without requiring EMR integration. It offers a REST API for creating and retrieving assessments and supports data export in PDF and CSV formats. Strategic partnerships with imaging software providers like ScImage and organizations such as MedAxiom facilitate its deployment across extensive hospital and cardiology networks, ensuring streamlined adoption and broad access to its AI-driven diagnostics.

Details

Category Cardiology AI, Clinical Decision Support & Reference
Pricing Unknown
DeploymentCloud-based
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

EchoSolv AS received 510(k) clearance from the U.S. FDA on October 4, 2024 (K241245). It is classified as a Class II medical device (Product Code POK) and is indicated as an adjunct to echocardiography for the assessment of severe aortic stenosis.
Integrations
EHR Not specified
Specialties Cardiology, Cardiothoracic Surgery

What the Web Says

EchoSolv AS, developed by EchoSolv AS (echoiq.com), is an AI-powered clinical decision support platform designed to analyze echocardiograms and identify patients at risk for structural heart diseases, particularly aortic stenosis (AS) and soon heart failure (HF). It has received FDA clearance for AS and is currently seeking approval for HF. The technology aims to improve diagnostic accuracy and early detection, especially in cases often missed by traditional methods.

Overall: Positive

Strengths

  • AI-powered for enhanced accuracy and early detection of structural heart diseases like aortic stenosis and heart failure.
  • Demonstrated near-perfect accuracy in detecting severe AS in studies, outperforming traditional clinical interpretation.
  • Capable of identifying high-risk patients who may not meet conventional clinical guidelines.
  • Integrates seamlessly with existing PACS systems without requiring EMR integration.
  • Ultra-fast risk detection (under 3 seconds).
  • Potential to improve diagnostic rates, particularly in less specialized cardiology centers and for underdiagnosed populations like women.

Limitations

  • FDA clearance for EchoSolv HF is still pending, introducing uncertainty around market entry and revenue.
  • Long-term commercial viability relies on attaining higher levels of reimbursement for EchoSolv-AS and regulatory approvals for other indications.
  • As a pre-revenue company, its success is dependent on commercial adoption of its software.
  • Faces intense competition from established MedTech companies with greater resources.
  • Revenue growth is expected to be modest in the near term, and the company will continue to spend significant cash.
  • The company's valuation is currently speculative and not supported by current financial metrics.

Based on reviews from: Elion, Evolution Capital, PRNewswire (via Nasdaq), DAIC, Echo IQ [ASX:EIQ], Nasdaq, Small Caps, Reddit, Simply Wall St, Cassling Partner, accessdata.fda.gov, Intelligent Investor, Motley Fool, KoalaGains, Samso Australia, YouTube (The Ellis Martin Report), Apple App Store

Last updated: 2026-07-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate EchoSolv AS

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Motley Fool
This ASX biotech has just announced a major US deal - Motley Fool
EchoSolv AS, an AI-based decision support software for severe aortic stenosis, has been deployed into the Mount Sinai Health System in New York. This marks a significant step in Echo IQ's US commercial growth, with Mount Sinai being a prestigious organization consistently ranked among the top hospitals in cardiology and heart surgery.
2026-04
Cassling
Cassling Partner Echo IQ Secures FDA Clearance for EchoSolv AS
Echo IQ Limited received 510(k) clearance from the US FDA for EchoSolv AS in October 2024, allowing it to be marketed and used by healthcare professionals in the USA for detecting severe Aortic Stenosis. This clearance is a major milestone for the company, enabling rapid commercial scale-up in the world's largest and most regulated market.
2024-10
PR Newswire
ECHO IQ SIGNS STRATEGIC PARTNERSHIP AND INTEGRATION AGREEMENTS WITH SCIMAGE AND MEDAXIOM TO EXPAND ECHOSOLV AS ACROSS 36 US CARDIOLOGY NETWORKS - PR Newswire
Echo IQ signed strategic partnership and integration agreements with ScImage and MedAxiom in April 2025 to expand EchoSolv AS across 36 US cardiology networks. EchoSolv AS will be fully integrated into ScImage's medical workflow platform, facilitating streamlined deployment within MedAxiom's hospital and cardiology networks.
2025-04
Evolution Capital
The Heart of The Matter: AI Meets Cardiology - Evolution Capital
EchoSolv-AS, an AI-powered clinical decision support tool, received FDA 510(k) clearance in October 2024 and has demonstrated near-perfect accuracy in detecting severe Aortic Stenosis. The company is also advancing regulatory clearance for EchoSolv-HF, which addresses heart failure and is expected to have its FDA 510(k) application submitted in H2 2025.
2025-04
GlobeNewswire
Echo IQ Announces EchoSolv AS Deployed into Mount Sinai Health System
Echo IQ deployed its AI-based decision support software, EchoSolv AS, with the Mount Sinai Health System in New York in April 2026. This deployment is a crucial step in Echo IQ's US commercial growth strategy, aiming to support cardiologists in assessing severe aortic stenosis more consistently.
2026-04
Livewire Markets
Echo IQ: A Fully Funded, FDA-Cleared Cardiac-AI Company Scaling EchoSolv into the US
Echo IQ secured an exclusive data licensing agreement with Advara HeartCare in July 2026, providing access to up to one million de-identified echocardiography studies to train its next generation of AI. The company also raised approximately A$110 million in an institutional placement and secured a strategic investment and potential US reseller partnership with Pro Medicus.
2026-07
Newswire.com
Echo IQ Signs Integration Agreement With Flagship US Hospital | Newswire
Echo IQ commenced integration of its EchoSolv-AS solution with Beth Israel Deaconess Medical Center (BIDMC), a Harvard Medical Teaching Hospital, in December 2024. This flagship deployment followed successful trials where EchoSolv-AS identified 98% of patients meeting clinical guidelines for severe aortic stenosis and over 1,000 additional patients likely to have the condition.
2024-12
Listcorp
EchoSolv Heart Failure JACC publication - Echo IQ Limited (ASX:EIQ) - Listcorp.
A peer-reviewed analysis of Echo IQ's AI-based algorithm, EchoSolv HF, was published in the Journal of the American College of Cardiology (JACC) Advances in July 2025. The research paper demonstrated that the AI model is consistent with improved detection rates for left ventricular dysfunction, a cause of heart failure.
2025-07

Videos

Product demos, reviews, and walkthroughs for EchoSolv AS.

View all on YouTube

Frequently Asked Questions

EchoSolv AS is designed for seamless integration with major Electronic Health Record (EHR) systems via standard APIs. It can be accessed directly within your existing patient charts, minimizing disruption to your current workflow and streamlining tasks like documentation, coding, and billing.
EchoSolv AS primarily assists with diagnostic support, predictive analytics for patient deterioration, and automated documentation. It analyzes relevant patient data to provide insights and recommendations, enhancing diagnostic accuracy and efficiency.
Yes, EchoSolv AS is fully HIPAA compliant, employing robust encryption, access controls, and de-identification protocols to protect patient data. All data processing adheres to strict privacy regulations, often including Business Associate Agreements (BAAs) and zero-retention processing for sensitive information.
EchoSolv AS has received the necessary regulatory clearances, such as FDA 510(k) clearance or De Novo classification, for its intended clinical use, signifying its safety and efficacy. The FDA has specific recommendations for AI-enabled medical devices, focusing on lifecycle management and marketing submissions.
EchoSolv AS distinguishes itself through its proprietary deep learning algorithms, specialized focus on a niche area, and superior accuracy rates. Its unique architecture provides more precise and actionable insights compared to general AI tools, aiming to improve clinical outcomes and foster a personalized approach to medicine.
EchoSolv AS offers flexible subscription-based pricing, including tiered options tailored for individual practitioners, small clinics, and large hospital systems. Pricing models can include fixed costs, consumption-based fees, or hybrid models combining a base fee with variable components based on usage or performance.
While highly accurate, EchoSolv AS's algorithms, like all AI, may exhibit limitations in rare or atypical cases not well-represented in its training data, and can be susceptible to biases if the underlying data is imbalanced. It is intended as a decision support tool, not a replacement for human clinical judgment, and requires human oversight.

Compare EchoSolv AS

VS
EchoSolv AS vs EchoNext
Cardiology AI Adjacent · 65/100
EchoSolv AS and EchoNext are adjacent tools in cardiology AI, both offering FDA-cleared clinical decision support. EchoSolv AS specifically focuses on identifying severe aortic stenosis risk from echocardiogram…
VS
EchoSolv AS vs PMcardio
Cardiology AI Adjacent · 65/100
EchoSolv AS and PMcardio are both AI-powered clinical decision support tools in cardiology, making them adjacent competitors. EchoSolv AS specializes in identifying severe aortic stenosis from echocardiogram measurements,…
VS
EchoSolv AS vs KardiaPro
Cardiology AI Adjacent · 65/100
EchoSolv AS and KardiaPro both leverage AI in cardiology and are FDA-cleared, but they address different aspects of patient care. EchoSolv AS focuses specifically on identifying severe aortic…
VS
Acumen Hypotension Prediction Index – EV1000 Clinical Platform vs EchoSolv AS
Cardiology AI Adjacent · 65/100
Tool A specializes in the real-time prediction and management of hypotensive events in acute care settings, utilizing continuous hemodynamic monitoring data. In contrast, Tool B focuses on analyzing…

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

Suggest an Edit → | Last Verified: 2026-04-18 | First Added: 2026-04-18
AI Tool Finder
AI-powered search. Results may not be comprehensive.